宫瘤宁胶囊联合米非司酮对子宫肌瘤患者的临床疗效

目的考察宫瘤宁胶囊联合米非司酮对子宫肌瘤患者的临床疗效。方法 83例患者随机分为对照组(41例)和观察组(42例),对照组给予米非司酮,观察组在对照组基础上加用宫瘤宁胶囊,疗程4周。检测临床疗效,肌瘤体积,血清MMP-9、VEGF、性激素(E₂、FSH、PRL),不良反应发生率变化。结果观察组总有效率高于对照组(P<0.05)。治疗后,2组肌瘤体积缩小,MMP-9、VEGF、性激素表达降低(P<0.05),以观察组更明显(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论宫瘤宁胶囊联合米非司酮可降低子宫肌瘤患者血清MMP-9、VEGF、性激素表达,临床疗效、安全性良好。

Clinical effects of Gongliuning Capsules combined with mifepristone on patients with hysteromyoma

AIM To investigate the clinical effects of Gongliuning Capsules combined with mifepristone on patients with hysteromyoma.METHODS Eighty-three patients were randomly assigned into control group(41 cases) for 4-week administration of mifepristone, and observation group(42 cases) for 4-week administration of both Gongliuning Capsules and mifepristone. The changes in clinical efficacy, myoma volume, serum MMP-9, VEGF and sex hormones(E2, FSH, PRL), and occurrence of adverse reactions were detected.RESULTS The observation group demonstrated higher total effective rate than the control group(P<0.05). After the treatment, the two groups displayed reduced myoma volume, and decreased MMP-9, VEGF and sex hormone expressions(P<0.05), especially for the observation group(P<0.05). No obvious difference in occurrence of adverse reactions was found between the two groups(P>0.05).CONCLUSION For the patients with hysteromyoma, Gongliuning Capsules combined with mifepristone can decrease serum MMP-9, VEGF and sex hormone expressions, exhibiting good clinical efficacy and safety.